Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2173-2179

  Urashima, Mitsuyoshi ^a   Teoh, Gerrard ^a   Ogata, Atsushi ^a   Chauhan, Dharminder ^a   Treon, Steven P ^a   Sugimoto, Yoshihisa ^a,b,c,d   Kaihara, Chiharu ^b   Matsuzaki, Masaharu ^b   Hoshi, Yasutaka ^b   Decaprio, James A ^a   Anderson, Kenneth C ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SRL INC   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P16;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CLINICAL ARTICLE; GENE EXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

B-LYMPHOCYTES; BONE MARROW; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; GENES, P16; HUMANS; LEUKEMIA, PLASMA CELL; LEUKEMIA, PLASMACYTIC; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED;

EID: 0030694727     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
2. Hirama, T., and Koeffler, H. P. Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86: 841-854, 1995.
3. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 55: 27-37, 1996.
4. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
5. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
6. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
7. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
8. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
9. INK4 gene inactivation in acute lymphocytic leukemia. Blood, 85: 3431-3436, 1995.
10. Takeuchi, S., Bartram, C. R., Seriu, T., Miller, C. W., Tobler, A., Janssen, J. W. G., Reiter, A., Ludwig W-D., Zimmermann, M., Schwaller, J., Lee, E., Miyoshi, I., and Koeffler, P. H. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/ MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood, 86: 755-760, 1995.
11. Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., Yazaki, Y., and Hirai, H. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 84: 2431-2435, 1994.
12. INK4B gene deletions in primary leukemias. Blood, 86: 311-315, 1995.
13. Dreyling, M. H., Bohlander, S. K., Le Beau, M. M., and Olopade, O. I. Refined mapping of genomic rearrangement involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood, 86: 1931-1938, 1995.
14. Fizzotti, M., Cimino, G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., and LoCoco, F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 85: 2685-2690, 1995.
15. Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J. L., Bauters, F., Wattel, E., and Feuau, P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85: 657-663, 1995.
16. Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., Kamada, N., Kobayashi, Y., Takemoto, Y., Kitani, T., Toyama, K., Ohtake, S., Yazaki, Y., Ueda, R., and Hirai, H. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood, 87: 4949-4958, 1996.
17. Serra, A., Gottardi, E., Delia Ragione, F., Saglio, G., and Iolascon, A. Involvement of the cyclin-dependent kinase 4-inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br. J. Haematol., 91: 625-629, 1995.
18. Gernone, A., Iolascon A., Pietrafesa, A., and Dammacco, F. p16 gene analysis in multiple myeloma (MM). Leukemia (Baltimore), 10: 1401-1402, 1996.
19. INK4C genes in multiple myeloma. Br. J. Haematol., 96: 98-102, 1997.
20. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
21. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
22. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Turnout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
23. Vertino, P. M., Yen, R. W., Gao, J., and Baylin, S. B. De novo methylation of CpG island sequences in human fibroblasts overexpressing (cytosine-5-)-methyltransferase. Mol. Cell. Biol., 16: 4555-4565, 1996.
24. Sakai, T., Toguchida, J., Ohtani, N., Yandell, D. W., Rapaport, J. M., and Dryja, T. P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet., 48: 880-888, 1991.
25. Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., Lineham, W. M., and Baylin, S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.
26. Rideout, W. M., III, Eversole-Cire, P., Spruck, C. H., III, Hustad, C. M., Coetzee, G. A., Gonzales, F. A., and Jones, P. A. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol. Cell. Biol., 14: 6143-6152, 1994.
27. Issa, J. P., Baylin, S. B., and Belinsky, S. A. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res., 56: 3655-3658, 1996.
28. Magewu, A. N., and Jones, P. A. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol. Cell. Biol., 14: 4225-4232, 1994.
29. Shen, J-C., Rideout, W. M., III, and Jones, P. A. High frequency mutagenesis by a DNA methyltransferase. Cell, 71: 1073-1080, 1992.
30. Bird, A. The essentials of DNA methylation. Cell, 70: 5-8, 1992.
31. Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Jung, W. E., Li, E., Weinberg, R. A., and Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81: 197-205, 1995.
32. Herman, J. G., Civin, C. I., Issa, J-P., Collector, M. I., Sharkis, S. J., and Baylin, S. B. Distinct patterns of inactivation of p15INK4B and p16 INK4A characterize the major types of hematological malignancies. Cancer Res., 57: 837-841, 1997.
33. Batova, A., Diccianni, M. B., Yu, J. C., Nobori, T., Link, M. P., Pullen, J., and Yu, A. L. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res., 57: 832-836, 1997.
34. Ng, M. H. L., Chung, Y. F., Lo, K. W., Wickham, N. W. R., Lee, J. C. K., and Huang, D. P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood, 89: 2500-2506, 1997.
35. Urashima, M., Chauhan, D., Uchiyama, H., Freeman, G. J., and Anderson, K. C. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 85: 1903-1912, 1995.
36. Hitzler, J. K., Martinez-Valdez, H., Bergsagel, D., Minden, M. D., and Messner, H. A. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My1 to 7 established from patients with advanced stage of the disease. Blood, 78: 1996-2004, 1991.
37. Aizawa, S., Yaguchi, M., Nakao, M., Toyama, K., Inokuchi, S., Imai, T., Uasuda, M., Nabeshima, R., and Hanada, H. Hematopoietic supportive function of human bone marrow stromal cell lines established by a recombinant SV40-adenovirus vector. Exp. Hematol., 22: 482-487, 1994.
38. INK4B tumor suppressor and immunoglobulin heavy chain genes: TGF β/IL-7 inhibitory signaling mechanism. Leukemia (Baltimore), 10: 1576-1583, 1996.
39. Urashima, M., Chauhan, D., Hatzianni, M., Ogata, A., Hollenbaugh, D., Aruffo, A., and Anderson, K. C. CD40 ligand triggers interleukin-6-mediated B cell differentiation. Leukemia Res., 20: 507-515, 1996.
40. Urashima, M., Ogata, A., Chauhan, D., Vidriales, M. B., Teoh, G., Hoshi, Y., Schlossman, R. L., DeCaprio, J. A., and Anderson, K. C. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood, 88: 2219-2227, 1996.
41. Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vidriales, M. B., Dedera, D. A., Schlossman, R. L., and Anderson, K. C. Transforming growth factor β1: differential effects on multiple myeloma versus normal B cells. Blood, 87: 1928-1938, 1996.
42. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
43. Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A., Sidransky, D., Ewen, M. E., and Rollins, B. J. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res., 55: 6200-6209, 1995.
44. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
45. Ausubel, F. M., Brent, R., Kingston R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struth, K. Current Protocols in Molecular Biology, pp. 2.03-2.14.3. New York: John Wiley & Sons, 1993.
46. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C-M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
47. Boyes, J., and Bird, A. Repression of genes by methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J., 11: 327-333, 1992.
48. Hsieh, C-L. Dependence of transcriptional repression on CpG methylation density. Mol. Cell. Biol., 14: 5487-5494, 1994.
49. Wang, J., and Walsh, K. Resistance of apoptosis conferred by CdK inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
50. Stone, S., Dayananth, P., and Kamb, A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res., 56: 3199-3202, 1996.
51. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M. J., Harousseau, J. L., Bataille, R., and Amiot, M. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res., 55: 3647-3653, 1995.
52. Bataille, R., Jourdan, M., Zhang, X. G., and Klein, B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest., 84: 2008-2011, 1989.
53. Greipp, P. R. Prognosis in myeloma. Mayo Clin. Proc., 69: 895-902, 1994.
54. Walker, D. G., Duan, W., Popovic, E. A., Kaye, A. H., Tomlinson, F. H., and Lavis, M. Homozygous deletions of multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res., 55: 20-23, 1995.
55. Okamoto, A, Hussain, S. P., Hagiwara, K., Spillare, E. A., Rusin, M. R., Demetrick, D. J., Serrano, M., Hannon, G. J., Shiseki, M., Zariwala, M., Xiong, Y., Beach, D. H., Yokota, J., and Harris, C. C. Mutations in the p16INK4/MTS1/CDKN2, p15INK4/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55: 1448-1451, 1995.